Menu
The role of risk stratification in new screenings (lung, prostate, gastric)
Summary
The following activities will be carried out: survey of risk stratification models and organisational approaches for new screening; analysis of European guidelines and options; definition of cost-effectiveness scenarios and conduction of pooled data analysis from pilot studies. with feedback fromWP10 for relevant models; systematic reviews and multidisciplinary analyses (consensus method) to identify knowledge and research gaps in risk-stratified screening for lung, prostate, and gastric cancers (informed by 8.1, 8.2, 8.3, 8.4, 8.5); feedback provision to WP10 on costeffectiveness analysis.
This task will be led by Unicancer, France, co-led by ISPRO, Italy.
Subscribe to our newsletter to get news and updates.
Subscribe to our newsletter to get news and updates.
Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor HADEA can be held responsible for them.
The general objective of EUCanScreen is to assure sustainable implementation of high-quality screening for breast, cervical and colorectal cancers, as well as implementation of the recently recommended screening programs – for lung, prostate and gastric cancers. EUCanScreen will facilitate the reduction of cancer burden and achieving equity across the EU.
This project has received funding from the European Union’s EU4HEALTH Programme under the Grant Agreement no 101162959
